



Personalized Radiotherapy in Cancer Care

Guest Editors:

Prof. Dr. Bin S. Teh

Department of Radiation
Oncology, Houston Methodist
Hospital, Houston, TX, USA

Dr. Waqar M. Haque

Department of Radiation
Oncology, Houston Methodist
Hospital, Houston, TX, USA

Deadline for manuscript
submissions:

15 October 2024

Message from the Guest Editors

Dear Colleagues,

In 2004, the 21-gene recurrence score (RS) was established as the first predictive gene test for patients with hormonal receptor positive and HER-2 negative breast cancer who would not benefit from chemotherapy. Since then, numerous predictive biomarkers have been discovered, which has allowed us to tailor treatments to patients to offer them the best chance of survival, while also minimizing treatment-related toxicity. While many of the new predictive biomarkers involve modified systemic therapy, the focus is now on optimizing radiation treatments. Predictive genetic tests and the presence of biomarkers are being studied to optimize radiation doses and volumes. This Special Issue hopes to highlight the current status and future plans of personalized radiation therapy for patients with cancer at different disease sites.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)